Recent progress in studies of miRNA and skin diseases

Journal of Dermatology

Volumn 42, Issue 6, 2015, Pages 551-558

  Jinnin, Masatoshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

melanoma; miRNA; psoriasis; scleroderma

Indexed keywords

BCL2 LIKE PROTEIN 10; BCL2 RELATED PROTEIN 10; CYCLIN E; CYCLIN E1; MICRORNA; MICRORNA 1266 5P; MICRORNA 146A 5P; MICRORNA 18A 5P; MICRORNA 196A 5P; MICRORNA 19A 3P; MICRORNA 203 3P; MICRORNA 21 5P; MICRORNA 214 3P; MICRORNA 221 3P; MICRORNA 222 3P; MICRORNA 223 3P; MICRORNA 29 3P; MICRORNA 424 5P; MICRORNA 7 5P; MICRORNA LET 7A 5P; MIRAVIRSEN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PEPTIDES AND PROTEINS; PROTEIN KINASE C; UNCLASSIFIED DRUG;

BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; DOWN REGULATION; EPIDERMOLYSIS; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HAIR ANALYSIS; HAIR LEVEL; HUMAN; KERATINOCYTE; MELANOMA; NONHUMAN; POLYMYOSITIS; PROTEIN EXPRESSION; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCLERODERMA; SKIN DISEASE; UPREGULATION; DRUG ERUPTION; GENETICS; LOCALIZED SCLERODERMA; SKIN TUMOR;

DERMATOMYOSITIS; DRUG ERUPTIONS; HUMANS; MELANOMA; MICRORNAS; PSORIASIS; SCLERODERMA, LOCALIZED; SKIN NEOPLASMS;

EID: 84930486154     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12904     Document Type: Review

References (54)

1. Maragkakis M, Alexiou P, Papadopoulos GL, et al,. Accurate microRNA target prediction correlates with protein repression levels. BMC Bioinformatics 2009; 10: 295.
2. Chinnathambi S, Wiechert S, Tomanek-Chalkley A, Winter MC, Bickenbach JR,. Treatment with the cancer drugs decitabine and doxorubicin induces human skin keratinocytes to express Oct4 and the OCT4 regulator mir-145. J Dermatol 2012; 39: 617-624.
3. Li P, He QY, Luo CQ,. Overexpression of miR-200b inhibits the cell proliferation and promotes apoptosis of human hypertrophic scar fibroblasts in vitro. J Dermatol 2014; 41: 903-911.
4. Wang Y, Wang K, Liang J, et al,. Differential expression analysis of miRNA in peripheral blood mononuclear cells of patients with non-segmental vitiligo. J Dermatol 2015; 42: 193-197.
5. van Dommelen SM, Vader P, Lakhal S, et al,. Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J Control Release 2012; 161: 635-644.
6. Chen X, Liang H, Zhang J, Zen K, Zhang CY,. Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell 2012; 3: 28-37.
7. Mitchell PS, Parkin RK, Kroh EM, et al,. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
8. Hanke M, Hoefig K, Merz H, et al,. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010; 28: 655-661.
9. Lefkowitz GK, Mukhopadhyay A, Cowing-Zitron C, Yu BD,. The post-apoptotic fate of RNAs identified through high-throughput sequencing of human hair. PLoS ONE 2011; 6: e27603.
10. Wang Z, Jinnin M, Kudo H, et al,. Detection of hair-microRNAs as the novel potent biomarker: evaluation of the usefulness for the diagnosis of scleroderma. J Dermatol Sci 2013; 72: 134-141.
11. Zhang L, Huang J, Yang N, et al,. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006; 103: 9136-9141.
12. Kanemaru H, Fukushima S, Yamashita J, et al,. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci 2011; 61: 187-193.
13. Felicetti F, Errico MC, Bottero L, et al,. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008; 68: 2745-2754.
14. Bertino JR, Banerjee D, Mishra PJ,. Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. Pharmacogenomics 2007; 8: 1625-1627.
15. Furer V, Greenberg J, Attur M, Abramson S, Pillinger M,. The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clin Immunol 2010; 136: 1-15.
16. Philippidou D, Schmitt M, Moser D, et al,. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res 2010; 70: 4163-4173.
17. Yamashita J, Iwakiri T, Fukushima S, et al,. The rs2910164 G>C polymorphism in microRNA-146a is associated with the incidence of malignant melanoma. Melanoma Res 2013; 23: 13-20.
18. Ikuta Y, Nakatsura T, Kageshita T, et al,. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin Cancer Res 2005; 11: 8079-8088.
19. Friedman EB, Shang S, de Miera EV, et al,. Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med 2012; 10: 155.
20. Greenberg E, Besser MJ, Ben-Ami E, et al,. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers 2013; 18: 502-508.
21. Shiiyama R, Fukushima S, Jinnin M, et al,. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res 2013; 23: 366-72.
22. Inada T, Fukushima S, Murai M, et al,. Hair shaft miRNA-221 levels as a new tumor marker of malignant melanoma. J Dermatol 2015; 42: 198-201.
23. Sonkoly E, Wei T, Janson PC, et al,. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS ONE 2007; 2: e610.
24. Zibert JR, Løvendorf MB, Litman T, Olsen J, Kaczkowski B, Skov L,. MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci 2010; 58: 177-185.
25. Ichihara A, Jinnin M, Yamane K, et al,. microRNA-mediated keratinocyte hyperproliferation in psoriasis vulgaris. Br J Dermatol 2011; 165: 1003-1010.
26. Ichihara A, Jinnin M, Oyama R, et al,. Increased serum levels of miR-1266 in patients with psoriasis vulgaris. Eur J Dermatol 2012; 22: 68-71.
27. Pivarcsi A, Meisgen F, Xu N, Ståhle M, Sonkoly E,. Changes in the level of serum microRNAs in patients with psoriasis after antitumour necrosis factor-α therapy. Br J Dermatol 2013; 169: 563-570.
28. Koga Y, Jinnin M, Ichihara A, et al,. Analysis of expression pattern of serum microRNA levels in patients with psoriasis. J Dermatol Sci 2014; 74: 170-171.
29. Tsuru Y, Jinnin M, Ichihara A, et al,. miR-424 levels in hair shaft are increased in psoriatic patients. J Dermatol 2014; 41: 382-5.
30. Oyama R, Jinnin M, Kakimoto A, et al,. Circulating microRNA associated with TNF-α signaling pathway in patients with plaque psoriasis. J Dermatol Sci 2011; 61: 209-211.
31. Hirao H, Jinnin M, Ichihara A, et al,. Detection of hair root miR-19a as a novel diagnostic marker for psoriasis. Eur J Dermatol 2013; 23: 807-811.
32. Ichihara A, Wang Z, Jinnin M, et al,. Upregulation of miR-18a-5p contributes to epidermal necrolysis in severe drug eruptions. J Allergy Clin Immunol 2014; 133: 1065-1074.
33. Eisenberg I, Eran A, Nishino I, et al,. Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci USA 2007; 104: 17016-17021.
34. Inoue K, Jinnin M, Yamane K, et al,. Down-regulation of miR-223 contributes to the formation of Gottron's papules in dermatomyositis via the induction of PKC. Eur J Dermatol 2013; 23: 160-167.
35. Okada Y, Jinnin M, Makino T, et al,. MIRSNP rs2910164 of miR-146a is associated with the muscle involvement in polymyositis/dermatomyositis. Int J Dermatol 2014; 53: 300-304.
36. Inoue K, Jinnin M, Hara Y, et al,. Serum levels of tenascin-C in collagen diseases. J Dermatol 2013; 40: 715-719.
37. Oshikawa Y, Jinnin M, Makino T, et al,. Decreased miR-7 expression in the skin and sera of patients with dermatomyositis. Acta Derm Venereol 2012; 93: 273-276.
38. Makino K, Jinnin M, Kajihara I, et al,. Circulating miR-142-3p levels in patients with systemic sclerosis. Clin Exp Dermatol 2012; 37: 34-39.
39. Sing T, Jinnin M, Yamane K, et al,. microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. Rheumatology (Oxford) 2012; 51: 1550-1556.
40. Shimada S, Jinnin M, Ogata A, et al,. Serum miR-21 levels in patients with dermatomyositis. Clin Exp Rheumatol 2013; 31: 161-162.
41. Inoue M, Jinnin M, Wang Z, et al,. microRNA level is raised in the hair shafts of the patients with dematomyositis in comparison with the normal subjects and sclerodermic patients. Int J Dermatol 2015; [forthcoming].
42. Maurer B, Stanczyk J, Jüngel A, et al,. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010; 62: 1733-1743.
43. van Rooij E, Sutherland LB, Thatcher JE, et al,. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105: 13027-13032.
44. Cheng J, Wang Y, Wang D, Wu Y,. Identification of collagen 1 as a post-transcriptional target of miR-29b in skin fibroblasts: therapeutic implication for scar reduction. Am J Med Sci 2013; 346: 98-103.
45. Honda N, Jinnin M, Kajihara I, et al,. TGF-β-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts. J Immunol 2012; 188: 3323-3331.
46. Makino K, Jinnin M, Hirano A, et al,. The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma. J Immunol 2013; 190: 3905-3915.
47. Nazari-Jahantigh M, Wei Y, Schober A,. The role of microRNAs in arterial remodelling. Thromb Haemost 2012; 107: 611-618.
48. Kawashita Y, Jinnin M, Makino T, et al,. Circulating miR-29a levels in patients with scleroderma spectrum disorder. J Dermatol Sci 2011; 61: 67-69.
49. Ihn H, Sato S, Tamaki T, et al,. Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res 1992; 284: 391-395.
50. Koba S, Jinnin M, Inoue K, et al,. Expression analysis of multiple microRNAs in each patient with scleroderma. Exp Dermatol 2013; 22: 489-491.
51. Takemoto R, Jinnin M, Wang Z, et al,. Hair miR-29a levels are decreased in patients with scleroderma. Exp Dermatol 2013; 22: 832-833.
52. Tamai K, Kaneda Y, Nakamura H, et al,. NF-κB decoy DNA for treatment of atopic dermatitis. Nihon Rinsho 2005; 63: 659-663.
53. Igawa K, Satoh T, Yokozeki H,. A therapeutic effect of STAT6 decoy oligodeoxynucleotide ointment in atopic dermatitis: a pilot study in adults. Br J Dermatol 2009; 160: 1124-1126.
54. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al,. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201.